Although the headline is not referencing Daraprim and Turing Pharmaceuticals, some of the content is about that, and there is an embedded video interviewing Shk

Although the headline is not referencing Daraprim and Turing Pharmaceuticals, some of the content is about that, and there is an embedded video interviewing Shkreli, the Turing CEO. I recommend watching it; I thought it was a very good interview. Shkreli makes his case much more effectively than I'd have predicted. Example: he claims that a treatment course of Daraprim costs less than other drugs that, in his opinion, are comparable (i.e. those other drugs are cures for other similar diseases).